MedTrace Logo

Effectiveness of Triple Therapy in COPD

NCT03724877 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8853

Last updated 2019-12-03

Study results available
· View outcomes & findings →

Summary

To assess the effectiveness of maintenance treatment of Chronic obstructive pulmonary disease (COPD) with the Long-acting beta2-agonist - long-acting muscarinic antagonists-inhaled corticosteroids (LABA-LAMA-ICS) combination with a LABA-LAMA combination on the risk of COPD exacerbation and the safety on the incidence of community acquired pneumonia.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS)

(LABA-LAMA-ICS)

DRUG

Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)

(LABA-LAMA)

Sponsors & Collaborators

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-10
Primary Completion
2018-11-12
Completion
2018-11-12

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03724877 on ClinicalTrials.gov